15 January 2014Biotechnology

Potter Clarkson announces changes at the top

UK law firm Potter Clarkson LLP has made changes to its team with the appointment of two senior managers.

The Nottingham-based firm, which specialises in patents and trademarks, has announced that Colin Baker will be its new managing partner.

Baker (below left), who focuses on the patenting of chemical inventions, has been a partner at the firm since 1999.

He has experience of proceedings before the European Patent Office Opposition Division and Boards of Appeal and has handled more than 100 cases.

Alongside Baker, Andrew Argyle has joined the firm as its new practice director.

Argyle (below right) focuses on commercial and civil litigation and previously worked as a partner at Shakespeares for 15 years.

"This change has been planned and rehearsed for several months," said Baker.

"The change will be seamless and is part of the evolution of our top tier firm which achieves its 125-year milestone this year."

Potter Clarkson LLP advises its clients on IP rights in fields including biotechnology, chemistry, engineering and computing.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
22 October 2025   Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ‘right way’ to manage IP, and how to get the best results from external counsel relationships.
Biotechnology
2 September 2025   Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Biotechnology
12 June 2025   Judges uphold PTAB’s finding that two Agilent patents are invalid | All claims of patents, which cover guide RNAs, found to be anticipated by prior art.